Literature DB >> 21814872

Changes of fecal Bifidobacterium species in adult patients with hepatitis B virus-induced chronic liver disease.

Min Xu1, Baohong Wang, Yiqi Fu, Yanfei Chen, Fengling Yang, Haifeng Lu, Yunbo Chen, Jiali Xu, Lanjuan Li.   

Abstract

The beneficial effects of Bifidobacteria on health have been widely accepted. Patients with chronic liver disease have varying degrees of intestinal microflora imbalance with a decrease of total Bifidobacterial counts. Since different properties have been attributed to different Bifidobacterium species and there is no information available for the detailed changes in the genus Bifidobacterium in patients with chronic liver disease heretofore, it is meaningful to investigate the structure of this bacterium at the species level in these patients. The aim of this study was to characterize the composition of intestinal Bifidobacterium in patients with hepatitis B virus-induced chronic liver disease. Nested-PCR-based denaturing gradient gel electrophoresis (PCR-DGGE), clone library, and real-time quantitative PCR were performed on the fecal samples of 16 patients with chronic hepatitis B (CHB patients), 16 patients with hepatitis B virus-related cirrhosis (HBV cirrhotics), and 15 healthy subjects (Controls). Though there was no significant difference in the diversity among the three groups (P = 0.196), Bifidobacterium dentium seems to be specifically enhanced in patients as the PCR-DGGE profiles showed, which was further validated by clone library and real-time quantitative PCR. In contrast to the B. dentium, Bifidobacterium catenulatum/Bifidobacterium pseudocatenulatum were detected less frequently in the predominant profile and by quantitative PCR in HBV cirrhotics than in the controls, and the level of this species was also significantly different between these two groups (P = 0.023). Although having no quantitative difference among the three groups, Bifidobacterium longum was less commonly detected in HBV cirrhotics than in CHB patients and Controls by quantitative PCR (P = 0.011). Thus, the composition of intestinal Bifidobacterium was deeply altered in CHB and HBV cirrhotic patients with a shift from beneficial species to opportunistic pathogens. The results provide further insights into the dysbiosis of the intestinal microbiota in patients with hepatitis B virus-induced chronic liver disease and might potentially serve as guidance for the probiotics interventions of these diseases.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21814872     DOI: 10.1007/s00248-011-9925-5

Source DB:  PubMed          Journal:  Microb Ecol        ISSN: 0095-3628            Impact factor:   4.552


  47 in total

1.  Intestinal microflora in patients with liver cirrhosis.

Authors:  Hai Ying Zhao; Hui Ji Wang; Zhi Lu; Shu Zhen Xu
Journal:  Chin J Dig Dis       Date:  2004

2.  Microbiomic analysis of the bifidobacterial population in the human distal gut.

Authors:  Francesca Turroni; Julian R Marchesi; Elena Foroni; Miguel Gueimonde; Fergus Shanahan; Abelardo Margolles; Douwe van Sinderen; Marco Ventura
Journal:  ISME J       Date:  2009-03-19       Impact factor: 10.302

3.  Mucosal bacterial microflora and mucus layer thickness in adolescents with inflammatory bowel disease.

Authors:  Krzysztof Fyderek; Magdalena Strus; Kinga Kowalska-Duplaga; Tomasz Gosiewski; Andrzej Wedrychowicz; Urszula Jedynak-Wasowicz; Małgorzata Sładek; Stanisław Pieczarkowski; Paweł Adamski; Piotr Kochan; Piotr B Heczko
Journal:  World J Gastroenterol       Date:  2009-11-14       Impact factor: 5.742

4.  Bifidobacterial diversity in human feces detected by genus-specific PCR and denaturing gradient gel electrophoresis.

Authors:  R M Satokari; E E Vaughan; A D Akkermans; M Saarela; W M de Vos
Journal:  Appl Environ Microbiol       Date:  2001-02       Impact factor: 4.792

5.  Distribution of bifidobacterial species in human intestinal microflora examined with 16S rRNA-gene-targeted species-specific primers.

Authors:  T Matsuki; K Watanabe; R Tanaka; M Fukuda; H Oyaizu
Journal:  Appl Environ Microbiol       Date:  1999-10       Impact factor: 4.792

6.  Hepatoprotective effect of lactic acid bacteria, inhibitors of beta-glucuronidase production against intestinal microflora.

Authors:  Song-Yi Han; Chul-Sung Huh; Young-Tae Ahn; Kwang-Sei Lim; Young-Jin Baek; Dong-Hyun Kim
Journal:  Arch Pharm Res       Date:  2005-03       Impact factor: 4.946

7.  Examination of faecal Bifidobacterium populations in breast- and formula-fed infants during the first 18 months of life.

Authors:  Laure C Roger; Adele Costabile; Diane T Holland; Lesley Hoyles; Anne L McCartney
Journal:  Microbiology       Date:  2010-09-23       Impact factor: 2.777

8.  Quantitative assessment of faecal bifidobacterial populations by real-time PCR using lanthanide probes.

Authors:  M Gueimonde; L Debor; S Tölkkö; E Jokisalo; S Salminen
Journal:  J Appl Microbiol       Date:  2007-04       Impact factor: 3.772

9.  Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis.

Authors:  T Kühbacher; S J Ott; U Helwig; T Mimura; F Rizzello; B Kleessen; P Gionchetti; M Blaut; M Campieri; U R Fölsch; M A Kamm; S Schreiber
Journal:  Gut       Date:  2006-01-09       Impact factor: 23.059

10.  Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study.

Authors:  Mariano Malaguarnera; Filippo Greco; Gloria Barone; Maria Pia Gargante; Michele Malaguarnera; Maria Antonietta Toscano
Journal:  Dig Dis Sci       Date:  2007-03-28       Impact factor: 3.199

View more
  42 in total

Review 1.  Probiotics and liver disease.

Authors:  Vishal Sharma; Shashank Garg; Sourabh Aggarwal
Journal:  Perm J       Date:  2013

2.  Qualitative and Semiquantitative Analysis of Fecal Bifidobacterium Species in Centenarians Living in Bama, Guangxi, China.

Authors:  Fang Wang; Guohong Huang; Da Cai; Danlei Li; Xiaolin Liang; Ting Yu; Peihong Shen; Haiyan Su; Jidong Liu; Hongcang Gu; Mouming Zhao; Quanyang Li
Journal:  Curr Microbiol       Date:  2015-03-25       Impact factor: 2.188

Review 3.  Interactions between the intestinal microbiome and liver diseases.

Authors:  Bernd Schnabl; David A Brenner
Journal:  Gastroenterology       Date:  2014-01-15       Impact factor: 22.682

Review 4.  Interplay between viruses and bacterial microbiota in cancer development.

Authors:  Dariia Vyshenska; Khiem C Lam; Natalia Shulzhenko; Andrey Morgun
Journal:  Semin Immunol       Date:  2017-06-09       Impact factor: 11.130

Review 5.  Probiotics for people with hepatic encephalopathy.

Authors:  Rohan Dalal; Richard G McGee; Stephen M Riordan; Angela C Webster
Journal:  Cochrane Database Syst Rev       Date:  2017-02-23

Review 6.  Microbiota and the gut-liver axis: bacterial translocation, inflammation and infection in cirrhosis.

Authors:  Valerio Giannelli; Vincenza Di Gregorio; Valerio Iebba; Michela Giusto; Serena Schippa; Manuela Merli; Ulrich Thalheimer
Journal:  World J Gastroenterol       Date:  2014-12-07       Impact factor: 5.742

7.  Assessment of microbiome variation during the perioperative period in liver transplant patients: a retrospective analysis.

Authors:  Haifeng Lu; Jianqing He; Zhongwen Wu; Wei Xu; Hua Zhang; Ping Ye; Jiezuan Yang; Shusen Zhen; Lanjuan Li
Journal:  Microb Ecol       Date:  2013-03-17       Impact factor: 4.552

8.  Alterations of the human gut microbiome in liver cirrhosis.

Authors:  Nan Qin; Fengling Yang; Ang Li; Edi Prifti; Yanfei Chen; Li Shao; Jing Guo; Emmanuelle Le Chatelier; Jian Yao; Lingjiao Wu; Jiawei Zhou; Shujun Ni; Lin Liu; Nicolas Pons; Jean Michel Batto; Sean P Kennedy; Pierre Leonard; Chunhui Yuan; Wenchao Ding; Yuanting Chen; Xinjun Hu; Beiwen Zheng; Guirong Qian; Wei Xu; S Dusko Ehrlich; Shusen Zheng; Lanjuan Li
Journal:  Nature       Date:  2014-07-23       Impact factor: 49.962

Review 9.  Gut microbiome, liver immunology, and liver diseases.

Authors:  Rui Wang; Ruqi Tang; Bo Li; Xiong Ma; Bernd Schnabl; Herbert Tilg
Journal:  Cell Mol Immunol       Date:  2020-12-14       Impact factor: 11.530

10.  Monosodium Glutamate Induces Changes in Hepatic and Renal Metabolic Profiles and Gut Microbiome of Wistar Rats.

Authors:  Kanokwan Nahok; Jutarop Phetcharaburanin; Jia V Li; Atit Silsirivanit; Raynoo Thanan; Piyanard Boonnate; Jarus Joonhuathon; Amod Sharma; Sirirat Anutrakulchai; Carlo Selmi; Ubon Cha'on
Journal:  Nutrients       Date:  2021-05-30       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.